JDM
MCID: CHL028
MIFTS: 55

Childhood Type Dermatomyositis (JDM)

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 12 15
Juvenile Dermatomyositis 12 75 53 59 17 72 33
Dermatomyositis, Childhood Type 72
Childhood Dermatomyositis 12
Juvenile Myositis 53
Juvenile Dm 59
Jdm 53
Jpm 53

Characteristics:

Orphanet epidemiological data:

59
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:14203
MeSH 44 D003882
NCIt 50 C27576
SNOMED-CT 68 1212005
ICD10 33 M33.0
MESH via Orphanet 45 C538250
ICD10 via Orphanet 34 M33.0
UMLS via Orphanet 73 C0263666 C2931785
Orphanet 59 ORPHA93672
UMLS 72 C0263666 C2931785

Summaries for Childhood Type Dermatomyositis

NIH Rare Diseases : 53 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema, muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures. Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to celiac disease 1 and myositis. An important gene associated with Childhood Type Dermatomyositis is IFIH1 (Interferon Induced With Helicase C Domain 1). The drugs Abatacept and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and heart, and related phenotypes are muscle weakness and fatigue

Wikipedia : 75 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 celiac disease 1 29.6 TNFRSF25 HLA-DQA1
2 myositis 28.7 TRIM33 TRIM21 NT5C1A IFIH1
3 muscular disease 28.0 TRIM33 TRIM21 NT5C1A MORC3 IFIH1
4 dermatomyositis 10.6
5 juvenile overlap myositis 10.5
6 interstitial lung disease 10.5
7 skin disease 10.5
8 lung disease 10.5
9 idiopathic inflammatory myopathy 10.4
10 dysphagia 10.4
11 systemic lupus erythematosus 10.3
12 hydrops, lactic acidosis, and sideroblastic anemia 10.3
13 neonatal lupus erythematosus 10.3 TRIM21 HLA-DQA1
14 type 1 diabetes mellitus 17 10.3 VWF TNFRSF25
15 muscular dystrophy 10.3
16 calcinosis 10.3
17 rheumatic disease 10.2
18 lupus erythematosus 10.2
19 juvenile polymyositis 10.2
20 adie pupil 10.2 TRIM21 TNFRSF25
21 visual epilepsy 10.2
22 subacute delirium 10.2
23 depression 10.2
24 seizure disorder 10.2
25 respiratory failure 10.2
26 diffuse scleroderma 10.2 TRIM21 TNFRSF25
27 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
28 enthesopathy 10.2
29 autoimmune disease of gastrointestinal tract 10.2 TNFRSF25 HLA-DQA1
30 heart block, congenital 10.2 TRIM21 TNFRSF25
31 maturity-onset diabetes of the young, type 1 10.1
32 diabetes mellitus 10.1
33 hypertrichosis 10.1
34 myocarditis 10.1
35 punctate epithelial keratoconjunctivitis 10.1 TRIM21 TNFRSF25
36 hypertriglyceridemia, familial 10.1
37 proteasome-associated autoinflammatory syndrome 1 10.1
38 pustulosis of palm and sole 10.1
39 psoriasis 10.1
40 alopecia 10.1
41 macrophage activation syndrome 10.1
42 raynaud phenomenon 10.1
43 polymyositis 10.1
44 vasculitis 10.0
45 autoimmune disease of musculoskeletal system 10.0 TRIM21 TNFRSF25
46 muscular dystrophy, duchenne type 10.0
47 thrombocytopenia 10.0
48 keratosis 10.0
49 pneumothorax 10.0
50 pericarditis 10.0

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

59 32 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
3 dry skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000958
4 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
5 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
6 telangiectasia of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0100585
7 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
8 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
9 mucosal telangiectasiae 59 32 hallmark (90%) Very frequent (99-80%) HP:0100579
10 myositis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100614
11 palpebral edema 59 32 hallmark (90%) Very frequent (99-80%) HP:0100540
12 elevated c-reactive protein level 59 32 hallmark (90%) Very frequent (99-80%) HP:0011227
13 elevated erythrocyte sedimentation rate 59 32 hallmark (90%) Very frequent (99-80%) HP:0003565
14 calcinosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0003761
15 elevated serum creatine kinase 32 hallmark (90%) HP:0003236
16 muscular hypotonia 59 32 frequent (33%) Frequent (79-30%) HP:0001252
17 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
18 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
19 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
20 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
21 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
22 cutaneous photosensitivity 59 32 frequent (33%) Frequent (79-30%) HP:0000992
23 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042
24 restrictive ventilatory defect 59 32 frequent (33%) Frequent (79-30%) HP:0002091
25 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
26 vasculitis 59 32 frequent (33%) Frequent (79-30%) HP:0002633
27 poikiloderma 59 32 frequent (33%) Frequent (79-30%) HP:0001029
28 muscle spasm 32 frequent (33%) HP:0003394
29 dysarthria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001260
30 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
31 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
32 pulmonary fibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002206
33 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
34 emg abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0003457
35 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
36 angina pectoris 59 32 occasional (7.5%) Occasional (29-5%) HP:0001681
37 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
38 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
39 limitation of joint mobility 59 32 occasional (7.5%) Occasional (29-5%) HP:0001376
40 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
41 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
42 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
43 cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001638
44 bundle branch block 59 32 occasional (7.5%) Occasional (29-5%) HP:0011710
45 hoarse voice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001609
46 elevated serum creatine phosphokinase 59 Very frequent (99-80%)
47 muscle cramps 59 Frequent (79-30%)

MGI Mouse Phenotypes related to Childhood Type Dermatomyositis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.5 HLA-DQA1 IFIH1 TNFRSF25 TRIM21 TRIM33 VWF
2 mortality/aging MP:0010768 9.23 DMBX1 IFIH1 MORC3 TNFRSF25 TRIM21 TRIM33

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2 Vaccines Phase 4
3 Immunologic Factors Phase 4
4 Immunosuppressive Agents Phase 4
5 Antirheumatic Agents Phase 4
6 Adrenocorticotropic Hormone Phase 4
7 Melanocyte-Stimulating Hormones Phase 4
8 beta-endorphin Phase 4
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
11
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
12
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
16
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
17
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
18
leucovorin Approved Phase 2, Phase 3 58-05-9 143 6006
19
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
22 Antifungal Agents Phase 3
23 Cyclosporins Phase 3
24 Calcineurin Inhibitors Phase 3
25 Bone Density Conservation Agents Phase 2, Phase 3
26 Prednisolone acetate Phase 3
27 Methylprednisolone Acetate Phase 3
28 glucocorticoids Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3
30 Gastrointestinal Agents Phase 2, Phase 3
31 Folic Acid Antagonists Phase 2, Phase 3
32 Hormones Phase 2, Phase 3
33 Anti-Inflammatory Agents Phase 2, Phase 3
34 Vitamin B9 Phase 2, Phase 3
35 Vitamin B Complex Phase 2, Phase 3
36 Folate Phase 2, Phase 3
37 Antineoplastic Agents, Hormonal Phase 2, Phase 3
38 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
39 Peripheral Nervous System Agents Phase 2, Phase 3
40 Dermatologic Agents Phase 2, Phase 3
41 Antimetabolites Phase 2, Phase 3
42 Antimetabolites, Antineoplastic Phase 2, Phase 3
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
44 Analgesics Phase 2, Phase 3
45 Analgesics, Non-Narcotic Phase 2, Phase 3
46 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
47
rituximab Approved Phase 2 174722-31-7 10201696
48
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
49 Neuroprotective Agents Phase 2
50 Antiemetics Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
6 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
7 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
8 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
9 Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
10 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
11 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
12 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
13 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
14 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
15 Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Unknown status NCT01217320
16 Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues Completed NCT00001973
17 Fatigue and Sleep in Children and Adolescents With Juvenile Idiopathic Arthritis: A Cross-Sectional Study Completed NCT03618680
18 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005
19 The CARRA Registry Completed NCT01697254
20 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
21 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
22 Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015 Recruiting NCT03432455
23 Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace Recruiting NCT03433638
24 AR-Power Patient Powered Research Network Recruiting NCT03840928
25 Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis Recruiting NCT00059748
26 Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders Recruiting NCT00055055
27 MYOPROSP: A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment and Delivery of Care in Adult Idiopathic Inflammatory Myopathy Recruiting NCT02468895
28 Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

41
Skeletal Muscle, Skin, Heart, Bone, Lung, T Cells, Testes

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 1041)
# Title Authors PMID Year
1
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. 38
30861625 2019
2
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. 38
31403247 2019
3
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. 38
31371656 2019
4
Using the tools of proteomics to understand the pathogenesis of idiopathic inflammatory myopathies. 38
31385878 2019
5
Juvenile polymyositis associated with ureteral necrosis: a diagnostic and therapeutic dilemma-case report and review of the literature. 38
31098736 2019
6
The identification of CCL18 as biomarker of disease activity in localized scleroderma. 38
31006523 2019
7
The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. 38
31388666 2019
8
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. 38
30690571 2019
9
Plasma exosomes from children with juvenile dermatomyositis are taken up by human aortic endothelial cells and are associated with altered gene expression in those cells. 38
31299993 2019
10
Patchy Lipodystrophy in a Young Adult With Juvenile Dermatomyositis: An Unusual Occurrence. 38
31356391 2019
11
Erythematous scaling lesions of the face, dorsal fingers, elbows, and knees together with symmetrical muscle weakness in a child. 38
31360483 2019
12
Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. 38
31292651 2019
13
Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. 38
31018961 2019
14
Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. 38
29770465 2019
15
Paediatric and adolescent rheumatic diseases: measures of disease activity. 38
31180784 2019
16
Sex Differences in Pediatric Rheumatology. 38
28849549 2019
17
Being on the juvenile dermatomyositis rollercoaster: a qualitative study. 38
31215480 2019
18
An international survey of developing classification criteria for juvenile dermatomyositis-scleroderma overlap. 38
31199482 2019
19
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. 38
30552836 2019
20
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. 38
31118099 2019
21
Rheumatology Panel in Pediatric Practice. 38
31102381 2019
22
[Juvenile dermatomyositis-what's new?] 38
31087132 2019
23
Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium to Longstanding Juvenile Dermatomyositis. 38
29953739 2019
24
[Cognitive dysfunction, loss of visual acuity and hearing can be symptoms of Susac syndrome]. 38
30990159 2019
25
Translation and validation of the Transition Readiness Assessment Questionnaire (TRAQ). 38
29457995 2019
26
Incidence and Prevalence of Idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study. 38
30833879 2019
27
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. 38
30869164 2019
28
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. 38
30715158 2019
29
Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. 38
30508195 2019
30
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. 38
30715143 2019
31
Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. 38
29532710 2019
32
Juvenile dermatomyositis with IgA nephropathy: case-based review. 38
30552457 2019
33
French expert opinion for the management of juvenile dermatomyositis. 38
30638764 2019
34
The Association of Short-term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis. 38
30714338 2019
35
Superior Mesenteric Artery Syndrome in a Case of Juvenile Dermatomyositis: A Unique Complication. 38
30664541 2019
36
ASYMPTOMATIC MULTIFOCAL PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH JUVENILE DERMATOMYOSITIS: OPTICAL COHERENCE ANGIOGRAPHY FINDINGS. 38
30614926 2019
37
Modelling disease activity in juvenile dermatomyositis: A Bayesian approach. 38
28589751 2019
38
Multispecialty approach for improving outcomes in juvenile dermatomyositis. 38
31213823 2019
39
Juvenile Dermatomyositis: A Case Report and Review of Literature. 38
30937233 2019
40
Co-existence of Juvenile dermatomyositis and psoriasis vulgaris with fungal infection: A case report and literature review. 38
30697901 2019
41
Coronary artery dilation associated with anti-synthetase syndrome in an adolescent. 38
30630507 2019
42
Connective Tissue Disorders in Childhood: Are They All the Same? 38
30620697 2019
43
Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases. 38
30740105 2019
44
Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology. 38
30706861 2019
45
B Cells as a Therapeutic Target in Paediatric Rheumatic Disease. 38
30837988 2019
46
Medications received by patients with juvenile dermatomyositis. 38
29773230 2018
47
Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. 38
30352204 2018
48
Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. 38
30547812 2018
49
Update on the clinical management of juvenile dermatomyositis. 38
30308133 2018
50
Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis. 38
30389421 2018

Variations for Childhood Type Dermatomyositis

Expression for Childhood Type Dermatomyositis

LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Pathways for Childhood Type Dermatomyositis

GO Terms for Childhood Type Dermatomyositis

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 8.62 TRIM21 HLA-DQA1

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.7 ZFAT TRIM33 TRIM21 SNRPC MORC3 IFIH1
2 zinc ion binding GO:0008270 9.02 TRIM33 TRIM21 SNRPC MORC3 IFIH1
3 single-stranded RNA binding GO:0003727 8.96 SNRPC IFIH1

Sources for Childhood Type Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....